Complexes and methods of reducing inflammation
Abstract
The present disclosure provides compositions comprising a complex comprising octadecylamine surface-functionalized nanodiamonds with dexamethasone bound to octadecylamine. In another aspect the invention comprises a method for reducing inflammation in a patient comprising locally administering a composition comprising a complex comprising octadecylamine surface-functionalized nanodiamonds with dexamethasone bound to octadecylamine. In a further aspect, the invention comprises a method for reducing inflammation in a patient comprising locally administering a composition comprising octadecylamine surface-functionalized nanodiamonds, wherein no therapeutic agent is bound to the nanodiamonds.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A complex comprising octadecylamine surface-functionalized nanodiamonds and dexamethasone, wherein dexamethasone is bound to the octadecylamine surface-functionalized nanodiamonds.
2 . The complex of claim 1 , wherein the dexamethasone forms a monolayer on the octadecylamine surface-functionalized nanodiamonds.
3 . The complex according to claim 1 wherein the complex has a particle size of less than about 7 μm.
4 . The complex according to claim 1 wherein the complex has a particle size of about 1-2 μm and/or a particle size of about 150 nm.
5 . A method of reducing inflammation in a patient, comprising administering the complex of claim 1 .
6 . The method of claim 5 wherein the site of inflammation is a lesion or diabetic ulcer.
7 . The method of claim 5 , wherein the inflammation is caused by rheumatoid arthritis, Crohn's disease, asthma, inflammatory bowel disease, venous leg ulcers, diabetes, psoriasis or multiple sclerosis.
8 . The method according to claim 5 , wherein the complex is delivered to the skin, the intestine, the lungs, trachea, or kidney of the subject.
9 . The method according to claim 5 , wherein the patient's macrophages phagocytose the octadecylamine surface-functionalized nanodiamonds.
10 . The method according to claim 5 , wherein the complex is locally administered.
11 . A method of reducing inflammation in a patient, comprising administering a composition comprising octadecylene surface-functionalized nanodiamonds, wherein the surface functionalized nanodiamonds do not bind a substantial amount of a therapeutic agent.
12 . The method of claim 11 wherein the site of inflammation is a lesion or diabetic ulcer.
13 . The method of claim 11 , wherein the inflammation is caused by rheumatoid arthritis, Crohn's disease, asthma, inflammatory bowel disease, venous leg ulcers, diabetes, psoriasis or multiple sclerosis.
14 . The method according to claim 11 , wherein the composition is delivered to the skin, the intestine, the lungs, trachea, or kidney of the subject.
15 . The method according to claim 11 , wherein the patient's macrophages phagocytose the surface-functionalized nanodiamonds.
16 . The method according to claim 11 , wherein the surface-functionalized nanodiamonds have a particle size of less than about 7 μm.
17 . The method according to claim 11 , wherein the surface-functionalized nanodiamonds have a particle size of about 1 μm.
18 . The method according to claim 11 , wherein the surface-functionalized nanodiamonds are locally administered.
19 . A method of reducing a level of M2A macrophages in a patient comprising administering a composition comprising octadecylene surface-functionalized nanodiamonds, wherein the surface functionalized nanodiamonds do not bind a substantial amount of a therapeutic agent.
20 . The complex according to claim 1 , wherein the nanodiamonds are aggregated, unaggregated or partially aggregated.Join the waitlist — get patent alerts
Track US2018289836A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.